ADAPTIVE BIOTECHNOLOGIES CORPORATION Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months of $161.35 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $161.35M.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $83.96M.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $24.78M.
- 2025-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months $80.85M.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months |
|---|---|
| 2026-06-30 | $161.35M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $83.96M 10-Q · filed 2026-05-05 |
| 2025-09-30 | $24.78M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $80.85M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $51.18M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $37.63M 10-K · filed 2025-03-03 |
| 2024-09-30 | $15.81M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $195.58M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $141.34M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $48.10M 10-K · filed 2024-02-29 |
| 2023-09-30 | $222.79M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $199.58M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $98.35M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $130.54M 10-K · filed 2023-02-14 |
| 2022-09-30 | $191.27K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $374.25M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $385.87M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $377.90M 10-K · filed 2022-02-15 |
| 2021-09-30 | $186.55M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $86.57M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $11.74M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $179.07M 10-K · filed 2021-02-24 |
| 2020-09-30 | $77.09M 10-Q · filed 2020-11-10 |
| 2020-03-31 | $5.77M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $35.21M 10-K · filed 2020-02-26 |
| 2019-09-30 | $53.98M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |